Having produced a new treatment, drug companies take great care to avoid testing it too exhaustively in patients. Now, such an assertion would provoke howls of protest from the drug industry, which would no doubt point out just how much clinical research it does (lots) and contrast this with the amount of non-industry development of new drugs (very little).

While some of this counter-argument is half true, it doesn't alter the fact that too much essential information about many new drugs is missing when these products …

Get access to this article and to all of thebmj.com for 14 daysSign up today for a 14 day free trial